What it's for (Indications)
- Basiliximab is specifically indicated for the prophylaxis of acute organ rejection in adult and pediatric *de novo* renal (kidney) transplant recipients.
- It is intended for use as part of an immunosuppressive regimen that typically includes cyclosporine (or tacrolimus) and corticosteroids.
- This induction therapy aims to reduce the incidence of acute rejection episodes during the critical early post-transplant period.
- It is crucial to note that basiliximab is not indicated for the treatment of established acute rejection episodes.
- Its primary role is to provide initial immunosuppression to prevent the immune system from mounting an aggressive response against the newly transplanted organ, thereby improving short-term graft survival rates and reducing the need for more intensive immunosuppressive therapies.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adult patients, the recommended total dose of basiliximab is 40 mg, administered in two separate 20 mg doses. The first 20 mg dose should be given intravenously (IV) within 2 hours prior to transplantation surgery. The second 20 mg dose should be administered IV on Day 4 post-transplantation. For pediatric patients weighing 35 kg or more, the adult dosing regimen of two 20 mg IV doses applies. For pediatric patients weighing less than 35 kg, the recommended total dose is 20 mg, administered as two 10 mg IV doses, with the first dose given within 2 hours prior to transplantation and the second dose on Day 4 post-transplantation. Each dose should be administered as an intravenous infusion over a period of 20 to 30 minutes through a central or peripheral vein. Proper reconstitution and dilution procedures must be followed strictly according to manufacturer guidelines before administration. |
Safety & Warnings
Common Side Effects
- Basiliximab is generally well-tolerated; however, as with all immunosuppressive agents, it carries a risk of various side effects.
- Common adverse reactions observed in clinical trials, typically reported at similar or slightly higher rates than placebo in combination with standard immunosuppression, include gastrointestinal disturbances such as constipation, nausea, vomiting, diarrhea, and abdominal pain.
- Other frequently reported side effects involve the central nervous system (e.
- g.
- , headache, insomnia, tremor), cardiovascular system (e.
- g.
- , hypertension, peripheral edema), and genitourinary system (e.
- g.
- , urinary tract infection).
- Patients may also experience anemia, pain, or fever.
- More serious risks include an increased susceptibility to infections (bacterial, viral, fungal, protozoal, including opportunistic infections) and malignancies (e.
- g.
- , lymphoproliferative disorders, skin cancer) due to the overall immunosuppressive regimen.
- Hypersensitivity reactions, though rare, can be severe.
Serious Warnings
- Black Box Warning: Only physicians experienced in immunosuppression therapy and management of organ transplantation patients should prescribe Simulect (basiliximab). The physician responsible for Simulect administration should have complete information requisite for the follow-up of the patient. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources.
- Severe acute hypersensitivity reactions, including anaphylaxis, urticaria, and angioedema, have been reported following the administration of basiliximab.
- Therefore, basiliximab should only be administered under close medical supervision in a facility equipped for the immediate treatment of such reactions.
- Due to its immunosuppressive properties, basiliximab increases the patient's susceptibility to infections, including opportunistic infections, and significantly elevates the risk of developing malignancies, particularly lymphoproliferative disorders and skin cancers, when used as part of a multi-drug immunosuppressive regimen.
- Patients should be counseled on these risks and monitored appropriately.
- There is limited data on re-treatment courses with basiliximab.
- Live attenuated vaccines should be avoided during basiliximab therapy, and the efficacy of inactivated vaccines may be diminished.
- Caution is advised for pregnant and lactating individuals; basiliximab is classified as Pregnancy Category B, and its excretion in human milk is unknown, necessitating a thorough risk-benefit assessment.
How it Works (Mechanism of Action)
Basiliximab is a chimeric (mouse/human) monoclonal antibody designed to selectively bind to and block the alpha subunit (CD25) of the human high-affinity interleukin-2 (IL-2) receptor. The IL-2 receptor, specifically its CD25 component, is predominantly expressed on the surface of activated T-lymphocytes, which are critical mediators of acute organ rejection. By binding with high affinity and specificity to the CD25 antigen, basiliximab effectively prevents the binding of IL-2, a key cytokine, to its receptor. This blockade inhibits the IL-2-mediated activation, proliferation, and differentiation of T-lymphocytes, thereby suppressing the immune response that would otherwise lead to the rejection of the transplanted organ. Crucially, basiliximab acts as an antagonist, preventing the activation of T-cells without causing T-cell depletion, making it an effective induction agent for preventing early acute rejection episodes in renal transplant recipients.
Commercial Brands (Alternatives)
No other brands found for this formula.